- Previous Close
0.0002 - Open
0.0002 - Bid 0.0002 x --
- Ask 0.0006 x --
- Day's Range
0.0002 - 0.0002 - 52 Week Range
0.0002 - 0.0117 - Volume
6,020 - Avg. Volume
102 - Market Cap (intraday)
1.284M - Beta (5Y Monthly) 2.08
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Feb 26, 2025 - Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company's development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 CannGros, FLS04 CannGros, and FLS05 CannGros. It is also involved in the import and distribution of Bedrocan CannGros, Bedica CannGros, and Bediol CannGros. The company was incorporated in 2018 and is based in Ansager, Denmark.
www.dancann.com12
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: DAN.F
View MorePerformance Overview: DAN.F
Trailing total returns as of 1/14/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DAN.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DAN.F
View MoreValuation Measures
Market Cap
1.18M
Enterprise Value
1.15M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.28
Price/Book (mrq)
0.45
Enterprise Value/Revenue
1.03
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-80.87%
Return on Equity (ttm)
-178.54%
Revenue (ttm)
8.22M
Net Income Avi to Common (ttm)
-59.11M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
-706k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-28.98M